Clinical trial · Interventional
Yallaferon in Chinese Population
a Multi-sites, Randomized, Parallel, Placebo-Controlled Clinical, Pilot Study to Evaluated the Efficacy and Safety of Recombinant Human Interferon Alpha-2b Gel (Yallaferon®) in HPV Infection
NCT02593968CI-TRIAL-00019676unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficacy of Yallaferon in Chinese population with HPV-16 and/or HPV-18.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HPV Infection | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo | Drug | — | UNRESOLVED |
| Recombinant Human Interferon a-2b Gel | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Treatment
- description
- subject were treated 3 periods with Yallaferon®; each period has interval 10 days ; one period included Yallaferon application for every other day for 10 times
- interventionNames
- Drug: Recombinant Human Interferon a-2b Gel
- type
- PLACEBO_COMPARATOR
- label
- Plcaebo
- description
- subject were treated 3 periods with Yallaferon® Plcaebo; each period has interval 10 days; one period included Yallaferon application for every other day for 10 times
- interventionNames
- Drug: Placebo
Primary outcomes (1)
- measure
- HPV-16 and/or HPV-18 negative conversion rate
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 25 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Age 25 to 65 years of age the sex life of female patients; * High-risk HPV 16 and/or 18 positive * Agree to sign ICF Exclusion Criteria: * Cervical intraepithelial neoplasia (CIN); * Combined with a severe fungal, trichomonas vaginitis; * Severe primary diseases associated with cardiovascular, liver, kidney and hematopoietic system; * Allergies or allergy to the drug known ingredients. * Within 30 days to accept other clinical trials of drugs or are participating in clinical trials; * Pregnant and lactating women and to be pregnant women; * The researchers do not consider it appropriate clinical trials.
References
Publications (0)
Data not yet available
No reference posted for this study.